Atlas Trials

A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)

Clinical trial NCT01968044 · COMPLETED

Trial details

NCT number
NCT01968044
Sponsor
LG Life Sciences
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Type 2 DM Patients With Moderate or Severe Renal Impairment
Start date
2013-10-01
Primary completion
2015-10-01
Enrollment
132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.